Article citationsMore>>

Zou, L., Fan, L. and Meng, F. (2023) The Impact of Vedolizumab Combined with Mesal on Intestinal Flora and Inflammatory Factors in Patients with Moderate-to-Severe Ulcerative Colitis. China Medical Innovation, 20, 41-45.

has been cited by the following article:

• TITLE: Advances in the Treatment of Refractory Moderate-to-Severe Ulcerative Colitis

  AUTHORS: Bing Lu, Qing Gao, Danni Luo, Guiying Zhang

  KEYWORDS: Refractory Ulcerative Colitis, Moderate-To-Severe UC

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.5, May 19, 2025

  ABSTRACT: Currently, the number of cases of refractory moderate-to-severe ulcerative colitis is increasing. Clinical investigations and research indicate that these cases account for over 70% of all ulcerative colitis, making them challenging to treat and manage. By integrating clinical practice experiences from both domestic and international sources, and through the continuous updating of research materials, this article provides a comprehensive overview of the treatment options for intractable moderate and severe ulcerative colitis, as well as a discussion of common clinical medications used in their management.